Introduction
Hereditary angioedema is an inherited disorder in which there is a quantitative or functional deficiency of the inhibitor of the activated first component of complement, Cl inhibitor (Cl-INH). It is characterized by recurrent attacks of non-pitting oedema of the extremities, face, larynx and abdomen including the bowel mucosa. An association of hereditary angioedema with various immunoregulatory disorders including systemic lupus erythematosus, lupus-like disease, Sj6gren's syndrome, autoimmune thyroid disease, inflammatory bowel disorder,' IgA deficiency,2 mesangiocapillary glomerulonephritis3 and coronary arteritis4 has been described. The use of the attenuated androgen danazol in preventing recurrent attacks of angioedema in hereditary angioedema was first described in 19765 and this drug is widely used as long-term maintenance therapy in this condition. IgA nephropathy, one of the commonest forms of nephropathy, is characterized by recurrent attacks of gross or microscopic haematuria and is diagnosed on renal biopsy by the presence of prominent IgA deposits in the mesangium by immunofluorescent techniques. We describe three members of a family with hereditary angioedema on danazol prophylaxis who have developed IgA nephropathy, an association not previously reported.
The family
The pedigree of the family is shown in Figure 1 and has been described in some detail in a family study of hereditary angio-neurotic oedema.6 In this report, case 1 appears at IV.2, case 2 at III.2, and cases 3 and 4 at IV.3 and IV.4, respectively.
Following the presentation of case 1 with painless haematuria in 1989, and the discovery that this was due to IgA nephropathy, we decided to review the other members of the family for haematuria and to check their renal function. Two types of hereditary angioedema have been described;'4 the common Type I, which affects approximately 85% of patients, is characterized by a quantitative deficiency of structurally and functionally normal Cl inhibitor and the variant Type II, affecting 15%, has a quantitative defect of inhibitor function, although the actual circulating levels may be normal or even slightly elevated. In the Type I disorder the deficiency appears to be due to an apparent lack of function of the one Cl inhibitor allele in the genome. Restriction fragment length polymorphism (RFLP) analysis has shown that this co-segregates with the disease in those families in whom it is detected but an abnormal RFLP is found in only 15-12% of Type I patients and partial deletions or insertions within the Cl inhibitor gene have been found in most of them. In the Type II cases, various point mutations affecting the active binding site of the enzyme have been described."3
As well as angioedema due to inherited Cl inhibitor deficiency, a similar clinical syndrome occurring in older patients, with no family history, has been described.'5 Subsequent studies have shown that there are also two types of the acquired disorder, the more common being found in patients with B cell lympho-proliferative disorders where antibodies to Cl inhibitor appear to arise through molecular mimicry with anti-idiotype antibodies while, rarely, autoantibodies directed against an epitope very adjacent to the active binding site of the protein have been described with no associated lympho-proliferative disorder. '3 The Cl inhibitor protein is a member of the serine inhibitors ('serpins') whose main target proteases are the Clr and Cls subunits of the Cl complex and, although inhibition of plasmin, kallikrein, factor XI and factor XII occurs, only inhibition of C1, Factor XII and kallikrein are thought to be physiologically important. '3 The mechanism of the production of angi- The role of androgen therapy in reducing the frequency and the severity of acute attacks in hereditary angioedema is well established and attenuated androgens such as danazol form the mainstay of prophylaxis in hereditary angioedema.5 Danazol increases the serum levels of Cl inhibitor in all phenotypes of this condition presumably because the androgen increases the synthesis of the deficient or defective protein.
Long-term danazol has been shown to be associated with various adverse effects including neuromusclular dysfunction, headaches, transient elevation of hepatic enzymes, menstrual irregularities in women and of particular relevance to this case, microscopic haematuria. 12 In this study, 13% ofpatients with hereditary angioedema on long-term therapy with danazol developed haematuria without impairment of renal function. Haemorrhagic cystitis was found to be present in some of these and in two patients renal biopsy revealed mild mesangial proliferation. The haematuria resolved with reduction of the dose of danazol.
Another study,' looking into the clinical immunoregulatory diseases associated with hereditary angioedema, found that in the majority any urinary abnormality -haematuria, active urinary sediment and proteinuria -developed before starting danazol therapy. This study also reported on five patients with renal disease associated with hereditary angioedema; four of these patients developed the urinary abnormality before danazol therapy was instituted. Renal biopsy showed membraneoproliferative glomerulonephritis in two and mild mesangial disease in the other three but in no case was IgA nephropathy found. Danazol therapy has been definitively associated with haematuria, but not with IgA nephropathy. On the contrary danazol has been used in the treatment of IgA nephropathy and one study has shown that danazol may increase the solubilization of glomerular immune complexes and reduce proteinuria in IgA nephropathy. 20 IgA nephropathy was first described by Berger and Hinglais in 196821 and it is now thought to be one of the commonest forms of glomerulonephritis. 22 The diagnostic immunopathologic pattern is the presence of mesangial deposits of IgA with C3 and properdin and sometimes other immunoglobulins, IgM and IgG. The pathogenesis of IgA nephropathy is not known but IgA containing immune complexes of IgA aggregates are thought to be involved. Their deposition in the renal mesangium followed by complement activation and release of other mediators including proteases and prostaglandins are postulated to mediate the glomerular injury.23 There is considerable evidence for the role ofcomplement in the pathogenesis of IgA nephropathy. The finding of the alternative pathway component properdin with C3 and membrane attack complex (C5b-9), with the relative absence of the classical pathway components Clq and C4, has been suggested as evidence for the importance ofalternative pathway activation in the pathogenesis of IgA nephropathy.23 A genetic predisposition of IgA nephropathy has been suggested by the familial clustering of the disease noticed by some studies. 24 No HLA haplotype has consistently been associated with IgA nephropathy, although in some countries, primarily Japan and France, an association with HLA DR4 and B35, respectively, has been reported;8'9 as reported above, none of our patients showed these HLA haplotypes. This is the first report of IgA nephropathy occurring in association with hereditary angioedema. In this family with hereditary angioedema and IgA nephropathy it is possible that the complement deficiency predisposed to the development of this disease. IgA nephropathy has been reported in three patients with a familial partial deficiency of a single complement protein -C2, properdin or H. 25 An increased frequency of the homozygous C4 null phenotype has been described in some patients with IgA nephropathy.'3 Complement is involved in various immunological processes including immunoregulation, immune clearance and immune complex solubilization and it has been suggested that these partial complement deficiencies inhibit the clearance of normally innocuous IgAcontaining immune complexes from the circulation or the glomerular mesangium.'5 The deficiency of the early components of the classical complement pathway that occurs in hereditary angioedema has been associated with various autoimmune diseases, although the mechanisms of this association is poorly defined. Although the complement activation in IgA nephropathy is thought to be predominantly via the alternative pathway, there is some evidence that classical pathway activation may not be uncommon. 23 The occurrence of IgA nephropathy in this family with hereditary angioedema may therefore imply a greater role for classical complement pathway activation in the pathogenesis of this nephropathy.
We think that the occurrence of IgA nephropathy in this family with hereditary angioedema is unlikely to be a coincidence. In our opinion it is likely that the underlying complement deficiency predisposed to its occurrence and we suggest that IgA nephropathy be added to the list of immunoregulatory disorders associated with hereditary angioedema.
